|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/15/19 Actinium Pharmaceuticals, Inc. 10-K 12/31/18 63:5.1M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 706K
2: EX-3.7 Certificate of Amendment to Actinium's Certificate HTML 17K
of Incorporation
3: EX-10.37 Consulting Agreement, Dated December 21, 2018, HTML 63K
Between Actinium Pharmaceuticals, Inc. and Nitya
Ray
4: EX-10.38 Amended and Restated at Market Issuance Sales HTML 237K
Agreement, Dated December 28, 2018, by and Among
Actinium Pharmaceuticals, Inc. and B. Riley Fbr,
Inc. and Jonestrading Institutional Services LLC
5: EX-10.39 Seventh Amendment to the 2013 Amended and Restated HTML 21K
Stock Plan, as Amended
6: EX-23.1 Consent of Gbh CPAs, Pc. HTML 18K
7: EX-23.2 Consent of Marcum LLP. HTML 18K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
11: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
18: R1 Document and Entity Information HTML 56K
19: R2 Consolidated Balance Sheets HTML 88K
20: R3 Consolidated Balance Sheets (Parenthetical) HTML 41K
21: R4 Consolidated Statements of Operations HTML 52K
22: R5 Consolidated Statement of Changes in Stockholders' HTML 72K
Equity
23: R6 Consolidated Statements of Cash Flows HTML 93K
24: R7 Description of Business and Summary of Significant HTML 60K
Accounting Policies
25: R8 Derivative Liabilities HTML 34K
26: R9 Prepaid Expenses and Other Current Assets HTML 24K
27: R10 Property and Equipment HTML 30K
28: R11 Commitments and Contingencies HTML 35K
29: R12 Equity HTML 79K
30: R13 Income Taxes HTML 43K
31: R14 Subsequent Event HTML 24K
32: R15 Description of Business and Summary of Significant HTML 105K
Accounting Policies (Policies)
33: R16 Description of Business and Summary of Significant HTML 36K
Accounting Policies (Tables)
34: R17 Derivative Liabilities (Tables) HTML 34K
35: R18 Prepaid Expenses and Other Current Assets (Tables) HTML 24K
36: R19 Property and Equipment (Tables) HTML 29K
37: R20 Commitments and Contingencies (Tables) HTML 23K
38: R21 Equity (Tables) HTML 48K
39: R22 Income Taxes (Tables) HTML 40K
40: R23 Description of Business and Summary of Significant HTML 27K
Accounting Policies (Details)
41: R24 Description of Business and Summary of Significant HTML 23K
Accounting Policies (Details 1)
42: R25 Description of Business and Summary of Significant HTML 33K
Accounting Policies (Details 2)
43: R26 Description of Business and Summary of Significant HTML 53K
Accounting Policies (Details Textual)
44: R27 Derivative Liabilities (Details) HTML 25K
45: R28 Derivative Liabilities (Details 1) HTML 40K
46: R29 Derivative Liabilities (Details Textual) HTML 33K
47: R30 Prepaid Expenses and Other Current Assets HTML 30K
(Details)
48: R31 Prepaid Expenses and Other Current Assets (Details HTML 21K
Textual)
49: R32 Property and Equipment (Details) HTML 39K
50: R33 Property and Equipment (Details 1) HTML 24K
51: R34 Property and Equipment (Details Textual) HTML 23K
52: R35 Commitments and Contingencies (Details) HTML 33K
53: R36 Commitments and Contingencies (Details Textual) HTML 68K
54: R37 Equity (Details) HTML 66K
55: R38 Equity (Details 1) HTML 69K
56: R39 Equity (Details Textual) HTML 360K
57: R40 Income Taxes (Details) HTML 35K
58: R41 Income Taxes (Details 1) HTML 75K
59: R42 Income Taxes (Details Textual) HTML 42K
60: R43 Subsequent Event (Details) HTML 47K
62: XML IDEA XML File -- Filing Summary XML 102K
61: EXCEL IDEA Workbook of Financial Reports XLSX 60K
12: EX-101.INS XBRL Instance -- atnm-20181231 XML 1.01M
14: EX-101.CAL XBRL Calculations -- atnm-20181231_cal XML 103K
15: EX-101.DEF XBRL Definitions -- atnm-20181231_def XML 479K
16: EX-101.LAB XBRL Labels -- atnm-20181231_lab XML 835K
17: EX-101.PRE XBRL Presentations -- atnm-20181231_pre XML 674K
13: EX-101.SCH XBRL Schema -- atnm-20181231 XSD 134K
63: ZIP XBRL Zipped Folder -- 0001213900-19-004269-xbrl Zip 107K
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER, PURSUANT TO
18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Actinium Pharmaceuticals, Inc. a Delaware corporation (the “Company”), on Form 10-K for the period ended December 31, 2018 as filed with the Securities and Exchange Commission (the “Report”), I, Steve O’Loughlin, Principal Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: March 15, 2019 | By: | /s/ Steve O’Loughlin |
| Steve O’Loughlin | ||
| Principal Financial Officer (Duly Authorized Officer, Principal Financial and Accounting Officer) | ||
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/15/19 | None on these Dates | ||
| For Period end: | 12/31/18 | |||
| List all Filings | ||||